Many dominant T cell variants decline during pregnancy and reappear afterward, possibly explaining why relapses of the autoimmune disease are less common when women are expecting.

Oligomannate, recently approved in China, is being met with some skepticism from researchers.

The initial findings from a small clinical trial of patients with multiple myeloma or sarcoma suggest that gene-edited immunotherapy is safe.

The 2019 Lasker medical and research awards celebrate advances in scientists’ understanding of T and B cells, Herceptin antibodies for treating breast cancer, and vaccine coverage around the globe.

The company Cell Vault offers to hold consumers’ T cells for later use, but scientists suggest the service would benefit very few users.

Injecting immunostimulants directly into the tumor is not a new strategy to stimulate the immune system, but the approach has seen a surge of interest in recent years.

Comparing the cells of cancer patients who did and did not respond to the immunotherapy could reveal biomarkers to predict who should receive it in the first place.

Those with two copies of the Δ32 allele in the CCR5 gene are 21 percent more likely to die by age 76, although it’s not clear why.

An experiment delves into how the microbiome shapes immunity.